Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. - Wikidata - wikimedia - TriplyDB

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

http://www.wikidata.org/entity/Q36262281

about

Use of Cell-Penetrating Peptides in Dendritic Cell-Based Vaccination Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology Epigenetic regulations of inflammatory cyclooxygenase-derived prostanoids: molecular basis and pathophysiological consequences Genetically modified T cells in cancer therapy: opportunities and challenges Dendritic cell-based vaccine efficacy: aiming for hot spots In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase Coordinated regulation of myeloid cells by tumours Therapeutic cancer vaccines and combination immunotherapies involving vaccination Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha.Monocyte-derived dendritic cells from patients with cervical intraepithelial lesions Antitumor Effect of KML-B-Treated Dendritic Cells via Induction of Lymphocyte Activation.Deconvolution of the gene expression profiles of valuable banked blood specimens for studying the prognostic values of altered peripheral immune cell proportions in cancer patients Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy Tumor antigen cross-presentation and the dendritic cell: where it all begins?Spontaneous apoptosis of blood dendritic cells in patients with breast cancer.Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.Dendritic cell subsets in health and disease.IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells.A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer.HLA-DR+ immature cells exhibit reduced antigen-presenting cell function but respond to CD40 stimulation Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma Immunomodulation by imiquimod in patients with high-risk primary melanoma Complete suppression of viral gene expression is associated with the onset and progression of lymphoid malignancy: observations in Bovine Leukemia Virus-infected sheep Effect of Chronic Uremia on the Cell Surface Expression of B7 Family Costimulatory Molecules in an HLA-A2 Transgenic Mouse Model of Chronic Kidney Disease.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Enhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12. A Preliminary Study.Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation Dendritic cell immunotherapy for breast cancer.Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia.Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression

P2860

Q26764861-A6CE31D6-6CDB-4B3B-AB23-1E987248BE8D Q26779184-DB54942B-8A83-476C-B07B-46E77831858E Q26825075-72B14DBA-AC17-4445-A0FD-F4465DEE96C3 Q26862642-0C0274BF-CAC5-4A7E-B307-7FE02BF27E1B Q27026627-CEA78748-08DB-485A-AD65-65466807DA8D Q28082680-A6670777-08AC-4122-AD40-0111B487F33D Q28303131-71BF34E5-9220-45F7-98D3-1AF358056C3A Q28386617-C17E1404-763F-407A-B784-649C986043EA Q28389108-CB60A190-7A94-45D7-8565-822E10BC3CA3 Q28392156-3B6AD39B-6C32-4B5F-9515-61F6BFB847C2 Q28392626-9B832513-4670-49B2-8D96-64366A044B2E Q28392943-45BAE855-E119-4C18-BBAC-ACB8B4DAD7E5 Q28395157-83F6DE28-8992-41B7-B55F-79233C5F959C Q28397609-0D0319FD-2247-4FE2-9BC2-E3DEB2C36C9A Q33347561-CE64F1E2-AEBA-4CE6-BD4A-1E300C0D7CB8 Q33598313-E987A767-E4A1-4059-984F-2877DE25E95D Q33786891-AA77EA48-5082-464C-870B-DE65CB3FAC3B Q33800793-115E56A1-B507-4CEE-826E-A0E5CBB207D5 Q33920298-0A15B762-D3DD-46BE-BC15-46B036F99D4A Q34210664-9F10D229-D200-4EBF-A5E1-03277016779E Q34480685-B25981BD-0B97-435E-AA5C-29D2DCCC1190 Q34502899-707EFF83-C750-4694-9972-C9B7B4D8DE21 Q34582889-76DD92FC-F794-48F6-B788-434C3548F8B8 Q34585798-121871C2-B9CD-430A-AB3B-37714F46FC64 Q34768502-3538A976-155E-435A-BF05-5AEABB82E402 Q34768526-EAAD67F2-A59C-4AB8-B7B2-43EA6269F72A Q34993170-762A9777-0188-47D6-86DF-FD883C201CC8 Q35043529-22522A69-B05B-4EC6-949F-38E258D24013 Q35078852-04B89FA8-623C-4CDE-BCA5-62A24B6DAD58 Q35590166-6CFE5130-5006-4A67-8EDC-DEA1515EA3F1 Q35940048-0FBF5D7F-989F-4B63-B305-28C7F6CDBC01 Q35996468-AEDAE5B5-1DCE-4AB9-96DB-37AE03BE342D Q36024656-91C634BD-5129-4A3C-8DF1-56E71E52FA6B Q36038020-2E29662A-4708-4492-8015-B4174FBCA146 Q36373352-ACAFCBAC-2F5C-4F84-A5F2-69B63130EEFF Q36480998-F6ABC405-3949-4E8C-BE2F-13078DA2C9B7 Q36498243-26589944-C017-428E-9B3B-7068387BC5A6 Q36611476-C1FA40ED-4645-45A1-A5EB-6F1FCAC79E75 Q36983304-28BA451E-0E55-4C92-A4A6-524DB2B43A2D Q36983876-46D4E928-0CF8-4F02-93B1-0FD7EF62C2B6

P2860

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

http://www.wikidata.org/entity/Q36262281

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

@ast

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

@en

type

label

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

@ast

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

@en

prefLabel

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

@ast

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

@en

P1433

Q36262281-AAD414C5-7B0A-4697-AE95-E25E548D4314

P1476

Q36262281-E8A837D6-A34C-451F-A429-29A65DED5A63

P2093

Q36262281-0763DEE8-295C-4106-BA76-30B09E7C3708

Q36262281-63AB35AF-1789-4D83-A64A-2DE7EA5AF3A3

Q36262281-C8A42F82-4674-4342-A299-F514F32B7933

P2860

Q36262281-061CC8FE-C985-4C9D-967F-E1D282391B8E

Q36262281-1A2E0D8A-0C1E-4919-B6AC-70859885DA37

Q36262281-1C8B3183-0043-402B-BD67-AE8FD0ECEA88

Q36262281-2329FBEA-4A29-4473-BAE9-51BCDF6060F7

Q36262281-25C0EEE3-F58E-48F5-90AA-6037C799290A

Q36262281-26D0C01A-D1C8-481C-B031-A69D5BD6928F

Q36262281-2E679F06-705A-4BF2-8F6E-BB334D4B5774

Q36262281-2FF6652F-CE24-4CBB-8C25-866B2A82804A

Q36262281-36E663B2-F51D-4760-B191-C53D95E960A8

Q36262281-3A94013B-B8F9-4E30-9E50-6E1ABF1226DD

P304

Q36262281-B615F724-C606-4347-BCED-A8EF47768024

P31

Q36262281-4E026360-0C86-4BB6-89A8-77E4B0458EE3

P356

Q36262281-68EC0BCE-7A11-4D47-92E0-A41BAC4AF511

P433

Q36262281-6194FBC1-0BD1-4B8E-9BBB-6241892F96E6

P478

Q36262281-5BDFF5A4-DFE7-4D1F-ACFD-044577761524

P577

Q36262281-32ED8C9C-054D-4ECD-9048-2069C8E6529E

P5875

Q36262281-0476AFB4-7570-4CD3-94DC-2C70EE09CDFD

P698

Q36262281-B46D2DC9-AD20-4AAE-A3AF-E90B71D7ABD8

P921

Q36262281-1F5E0C6B-E23B-47ED-AF9A-C0B0DA773F11

P356

J.1440-1711.2005.01371.X

P1433

Immunology & Cell Biology

P1476

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

@en

P2093

Alberto Pinzon-Charry

http://www.w3.org/2001/XMLSchema#string

J Alejandro López

http://www.w3.org/2001/XMLSchema#string

Tammy Maxwell

http://www.w3.org/2001/XMLSchema#string

P2860

Immunobiology of dendritic cells

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Nitric oxide (NO): an effector of apoptosis.

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.

Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells.

A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

Mouse and human dendritic cell subtypes.

Immunologic mechanisms of antitumor activity.

P304

451-461

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1440-1711.2005.01371.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7589989

http://www.w3.org/2001/XMLSchema#string

P698

16174093

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression